161 related articles for article (PubMed ID: 38428864)
21. Prognostic Impact of Pretreatment 2-[
Albano D; Dondi F; Mazzoletti A; Bellini P; Giubbini R; Bertagna F
Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34069203
[No Abstract] [Full Text] [Related]
22. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
23. [Value of
Zhang YY; Chen WY; Cui YP; Gao XR; Hu JX; Li ZZ; Hu K
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1342-1249. PubMed ID: 30295248
[TBL] [Abstract][Full Text] [Related]
24. Multiple metabolic parameters and visual assessment of
Ren Y; Liu J; Wang L; Luo Y; Ding X; Shi A; Liu J
Abdom Radiol (NY); 2020 Nov; 45(11):3569-3580. PubMed ID: 32274551
[TBL] [Abstract][Full Text] [Related]
25. Standardized uptake value for (18)F-fluorodeoxyglucose is correlated with a high International Prognostic Index and the presence of extranodal involvement in patients with diffuse large B-cell lymphoma.
Akkas BE; Vural GU
Rev Esp Med Nucl Imagen Mol; 2014; 33(3):148-52. PubMed ID: 24094371
[TBL] [Abstract][Full Text] [Related]
26. [Prognostic Value of
Su JM; Zheng QZ; Huang WR; Deng J; Wu J; Lu HQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1181-1186. PubMed ID: 34362500
[TBL] [Abstract][Full Text] [Related]
27. Prognostic analysis of interim
Yuan L; Kreissl MC; Su L; Wu Z; Hacker M; Liu J; Zhang X; Bo Y; Zhang H; Li X; Li S
Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):478-488. PubMed ID: 30382301
[TBL] [Abstract][Full Text] [Related]
28. Direct comparison of visual and quantitative bone marrow FDG-PET/CT findings with bone marrow biopsy results in diffuse large B-cell lymphoma: does bone marrow FDG-PET/CT live up to its promise?
Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
Acta Radiol; 2015 Oct; 56(10):1230-5. PubMed ID: 25387723
[TBL] [Abstract][Full Text] [Related]
29. Predictive value of clinical characteristics and baseline
Huang W; Chao F; Li L; Gao Y; Qiu Y; Wang W; Gao J; Han X; Kang L
Quant Imaging Med Surg; 2023 Dec; 13(12):8571-8586. PubMed ID: 38106313
[TBL] [Abstract][Full Text] [Related]
30. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma.
Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
Am J Hematol; 2014 Jul; 89(7):726-31. PubMed ID: 24711255
[TBL] [Abstract][Full Text] [Related]
31. Utility of Bone Marrow Biopsy and Aspirate for Staging of Diffuse Large B Cell Lymphoma in the Era of Positron Emission Tomography With 2-Deoxy-2-[Fluorine-18]fluoro-deoxyglucose Integrated With Computed Tomography.
Vishnu P; Wingerson A; Lee M; Mandelson MT; Aboulafia DM
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):631-636. PubMed ID: 28684378
[TBL] [Abstract][Full Text] [Related]
32. The prognostic significance of whole-body and spleen MTV (metabolic tumor volume) scanning for patients with diffuse large B cell lymphoma.
Yamanaka S; Miyagawa M; Sugawara Y; Hasebe S; Fujii T; Takeuchi K; Tanaka K; Yakushijin Y
Int J Clin Oncol; 2021 Jan; 26(1):225-232. PubMed ID: 33097970
[TBL] [Abstract][Full Text] [Related]
33. Predictive value of F-18 FDG PET/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants.
Xie M; Wu K; Liu Y; Jiang Q; Xie Y
Med Oncol; 2015 Jan; 32(1):446. PubMed ID: 25511321
[TBL] [Abstract][Full Text] [Related]
34. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
Wu LL; Liang JH; Wang L; Xu W; Ding CY
Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850
[No Abstract] [Full Text] [Related]
35. Evaluation of the prognostic value of the metabolic volumetric parameters calculated with
Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Rodríguez Carrillo JL; Dotor de Lama A; Navarro Matilla MB; Mitjavila Casanovas M
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2022; 41(4):215-222. PubMed ID: 35469793
[TBL] [Abstract][Full Text] [Related]
36. The prognostic value of end-of-treatment FDG-PET/CT in diffuse large B cell lymphoma: comparison of visual Deauville criteria and a lesion-to-liver SUV
Li YH; Zhao YM; Jiang YL; Tang S; Chen MT; Xiao ZZ; Fan W; Hu YY; Zhang X
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1311-1321. PubMed ID: 34651231
[TBL] [Abstract][Full Text] [Related]
37. Can metabolic tumor parameters on primary staging
Okuyucu K; Alagoz E; Ince S; Ozaydin S; Arslan N
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(1):9-14. PubMed ID: 28733137
[TBL] [Abstract][Full Text] [Related]
38. Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy.
Sjöholm T; Korenyushkin A; Gammelgård G; Sarén T; Lövgren T; Loskog A; Essand M; Kullberg J; Enblad G; Ahlström H
Cancer Imaging; 2022 Dec; 22(1):76. PubMed ID: 36575477
[TBL] [Abstract][Full Text] [Related]
39. Fluorodeoxyglucose-Positron Emission Tomography Predicts Bone Marrow Involvement in the Staging of Follicular Lymphoma.
St-Pierre F; Broski SM; LaPlant BR; Maurer MJ; Ristow K; Thanarajasingam G; Macon WR; Habermann TM; Witzig TE
Oncologist; 2020 Aug; 25(8):689-695. PubMed ID: 32319706
[TBL] [Abstract][Full Text] [Related]
40. 18F-FDG PET/CT in visceral leishmaniasis: uptake patterns in the context of a multiannual outbreak in Northern Italy.
Zanoni L; Varani S; Attard L; Morigi JJ; Vanino E; Ortalli M; Fonti C; Viale P; Re MC; Fanti S; Ambrosini V
Ann Nucl Med; 2019 Sep; 33(9):716-723. PubMed ID: 31254270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
